Characteristics of the overall cohort of patients who effectively received allogenic SCTs
| Patients . | Allogeneic HSCT, N = 164 . | Myeloablative, n = 117 . | RIC, n = 47 . | P* . |
|---|---|---|---|---|
| Median follow-up for alive patients (range), mo | 88 (16-119) | 88 (30-119) | 88 (16-119) | NS |
| Median age (range), y | 44 (17-60) | 39 (17-50) | 54 (34-60) | < .001 |
| Male sex (%) | 84 (51) | 67 (57) | 17 (36) | .02 |
| Previous solid tumor | 4 | 3 | 1 | NS |
| Performance status (%) | ||||
| 0-1 | 151 (92) | 108 (92.3) | 43 (91.5) | NS |
| 2 | 13 (8) | 9 (7.7) | 4 (8.5) | |
| Median initial WBC count (range), G/L | 11.8 (0.7-308) | 12.6 (0.7-308) | 9.3 (1-159) | NS |
| FAB classification | ||||
| (0/1/2/4/5/6/7) | 8/37/36/29/13/5/0 | 5/29/25/21/12/4/0 | 3/8/11/8/1/1/0 | NS |
| Not classified | 36 | 21 | 15 | |
| Karyotype | ||||
| Not evaluable (%) | 2 (1.2) | 1 (0.8) | 1 (2.1) | |
| Failure | 12 (7.3) | 10 (8.5) | 2 (4.3) | |
| Partial failure | 7 (4.2) | 6 (5.2) | 1 (2.1) | |
| Evaluable (%)† | ||||
| Favorable (1) | 18 (10.9) | 14 (12) | 4 (8.5) | |
| Intermediate (2) | 101 (61.5) | 72 (61.5) | 29 (61.7) | |
| High-risk (3) | 24 (14.6) | 14 (12) | 10 (21.3) | NS |
| First randomization (%) | ||||
| Idarubicin | 88 (53.6) | 59 (50.4) | 29 (61.7) | |
| Daunorubicin | 76 (46.3) | 58 (49.6) | 18 (38.3) | NS‡ |
| Complete remission (%) | ||||
| CR in one course | 120 (73.2) | 87 (74.3) | 33 (70.2) | |
| CR in two courses | 44 (26.8) | 30 (25.7) | 14 (29.8) | .03 |
| Donor-recipient CMV serostatus (%) | ||||
| +/+ | 44 (26.8) | 26 (22.2) | 18 (38.3) | |
| +/− | 22 (13.4) | 17 (14.5) | 5 (10.6) | |
| −/+ | 26 (15.9) | 15 (12.8) | 11 (23.4) | |
| −/− | 65 (39.6) | 52 (44.4) | 13 (27.7) | .04 |
| Missing | 7 (4.3) | 7 (6) | 0 | |
| Donor-recipient sex match (%) | ||||
| Male-male | 48 (29.3) | 38 (32.5) | 10 (21.3) | |
| Male-female | 43 (26.2) | 29 (24.8) | 14 (29.8) | |
| Female-male | 34 (20.7) | 27 (23) | 7 (14.9) | |
| Female-female | 33 (20.1) | 17 (14.5) | 16 (34) | .03 |
| Missing | 6 (3.7) | 6 (5.1) | 0 | |
| Type of donor (%) | ||||
| HLA-identical sibling | 162 (98.8) | 115 (98.3) | 47 (100) | |
| Mismatched relative | 2 (1.2) | 2 (1.7) |
| Patients . | Allogeneic HSCT, N = 164 . | Myeloablative, n = 117 . | RIC, n = 47 . | P* . |
|---|---|---|---|---|
| Median follow-up for alive patients (range), mo | 88 (16-119) | 88 (30-119) | 88 (16-119) | NS |
| Median age (range), y | 44 (17-60) | 39 (17-50) | 54 (34-60) | < .001 |
| Male sex (%) | 84 (51) | 67 (57) | 17 (36) | .02 |
| Previous solid tumor | 4 | 3 | 1 | NS |
| Performance status (%) | ||||
| 0-1 | 151 (92) | 108 (92.3) | 43 (91.5) | NS |
| 2 | 13 (8) | 9 (7.7) | 4 (8.5) | |
| Median initial WBC count (range), G/L | 11.8 (0.7-308) | 12.6 (0.7-308) | 9.3 (1-159) | NS |
| FAB classification | ||||
| (0/1/2/4/5/6/7) | 8/37/36/29/13/5/0 | 5/29/25/21/12/4/0 | 3/8/11/8/1/1/0 | NS |
| Not classified | 36 | 21 | 15 | |
| Karyotype | ||||
| Not evaluable (%) | 2 (1.2) | 1 (0.8) | 1 (2.1) | |
| Failure | 12 (7.3) | 10 (8.5) | 2 (4.3) | |
| Partial failure | 7 (4.2) | 6 (5.2) | 1 (2.1) | |
| Evaluable (%)† | ||||
| Favorable (1) | 18 (10.9) | 14 (12) | 4 (8.5) | |
| Intermediate (2) | 101 (61.5) | 72 (61.5) | 29 (61.7) | |
| High-risk (3) | 24 (14.6) | 14 (12) | 10 (21.3) | NS |
| First randomization (%) | ||||
| Idarubicin | 88 (53.6) | 59 (50.4) | 29 (61.7) | |
| Daunorubicin | 76 (46.3) | 58 (49.6) | 18 (38.3) | NS‡ |
| Complete remission (%) | ||||
| CR in one course | 120 (73.2) | 87 (74.3) | 33 (70.2) | |
| CR in two courses | 44 (26.8) | 30 (25.7) | 14 (29.8) | .03 |
| Donor-recipient CMV serostatus (%) | ||||
| +/+ | 44 (26.8) | 26 (22.2) | 18 (38.3) | |
| +/− | 22 (13.4) | 17 (14.5) | 5 (10.6) | |
| −/+ | 26 (15.9) | 15 (12.8) | 11 (23.4) | |
| −/− | 65 (39.6) | 52 (44.4) | 13 (27.7) | .04 |
| Missing | 7 (4.3) | 7 (6) | 0 | |
| Donor-recipient sex match (%) | ||||
| Male-male | 48 (29.3) | 38 (32.5) | 10 (21.3) | |
| Male-female | 43 (26.2) | 29 (24.8) | 14 (29.8) | |
| Female-male | 34 (20.7) | 27 (23) | 7 (14.9) | |
| Female-female | 33 (20.1) | 17 (14.5) | 16 (34) | .03 |
| Missing | 6 (3.7) | 6 (5.1) | 0 | |
| Type of donor (%) | ||||
| HLA-identical sibling | 162 (98.8) | 115 (98.3) | 47 (100) | |
| Mismatched relative | 2 (1.2) | 2 (1.7) |
SCT indicates stem cell transplantation; WBC, white blood cell; FAB, French-American-British; NS, non significant; and CR, complete remission.
Explain symbol.
Karyotype: (1) t(8;21) or inv(16); (2) all other chromosomal abnormalities; (3) high risk: −5, 5q−, −7, 3q abnormalities, t(6;9), multiple abnormalities (more than five abnormalities).
Explain symbol.